Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 3,221,253 | 2,853,915 | 2,419,226 | 2,096,039 | 1,846,275 |
| Cost of Goods | 717,442 | 580,235 | 532,062 | 503,023 | 470,515 |
| Gross Profit | 2,503,811 | 2,273,680 | 1,887,164 | 1,593,016 | 1,375,760 |
| Operating Expenses | 2,094,775 | 1,789,701 | 1,701,452 | 1,432,065 | 1,458,616 |
| Operating Income | 409,478 | 484,214 | 185,774 | 160,974 | -82,341 |
| Interest Expense | 10,899 | 12,666 | 17,335 | 15,970 | 15,337 |
| Other Income | 83,901 | 70,215 | 20,124 | 4,572 | 22,328 |
| Pre-tax Income | 482,480 | 541,763 | 188,563 | 149,576 | -75,350 |
| Income Tax | 133,579 | 114,904 | 20,918 | 8,015 | -11,270 |
| Net Income Continuous | 348,901 | 426,859 | 167,645 | 141,561 | -64,080 |
| Net Income | $348,901 | $426,859 | $167,645 | $141,561 | $-64,080 |
| EPS Basic Total Ops | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 |
| EPS Basic Continuous Ops | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 |
| EPS Diluted Total Ops | 1.80 | 2.21 | 0.87 | 0.75 | -0.35 |
| EPS Diluted Continuous Ops | 1.77 | 2.17 | 0.88 | 0.75 | -0.35 |
| EPS Diluted Before Non-Recurring Items | N/A | 2.75 | 1.23 | 0.89 | 0.25 |
| EBITDA(a) | $484,234 | $572,295 | $280,932 | $265,986 | $30,853 |